The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers - Tabular View

Tracking Information

First Received Date ^ICMJE

December 20, 2005

Last Updated Date

May 6, 2008

Start Date ^ICMJE

July 2004

Primary Completion Date

October 2007 (final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

Brain metabolic activity (FDG) in response to craving and neutral cues. [ Time Frame: 30-40 minutes ] [ Designated as safety issue: No ]

Original Primary Outcome Measures ^ICMJE

Brain metabolic activity (FDG) in response to craving and neutral cues.

Change History

Complete list of historical versions of study NCT00267813 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Subjective ratings of craving [ Time Frame: 10 minutes ] [ Designated as safety issue: No ]

Original Secondary Outcome Measures ^ICMJE

Subjective ratings of craving

Descriptive Information

Brief Title ^ICMJE

The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers

Official Title ^ICMJE

The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers.

Brief Summary

Detailed Description

Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban)for 2 months. We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity after exposure to videotapes showing smoking and neutral scenes in Positron Emission Tomography using FDG. There were 2 scanning sessions, one with a smoking videotape and one with a neutral video separated by a week. So far we have compared the brain's metabolic activity in 6 abstinent smokers and 6 still smokers.

Study Phase

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study

Condition ^ICMJE

Nicotine Dependence

Intervention ^ICMJE

Drug: Bupropion (Zyban)

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

October 2007

Primary Completion Date

October 2007 (final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Cigarette smokers (over 1 pack a day)
Age 20-65, male-females

Exclusion Criteria:

Dependence on other substances
Psychiatric diagnosis
Neurological disorder
Obesity
Young persons
Pregnant women

Gender

Both

Ages

20 Years to 65 Years

Accepts Healthy Volunteers

Yes

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Israel

Administrative Information

NCT ID ^ICMJE

NCT00267813

Responsible Party

Dr. Aviv M. Weinstein, Sourasky Medical Center Tel Aviv

Study ID Numbers ^ICMJE

TASMC-O5-EE-065-CTIL

Study Sponsor ^ICMJE

Tel-Aviv Sourasky Medical Center

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator:	Einat Even-Sapir, M.D, Ph.D	Tel-Aviv Sourasky Medical Center
Principal Investigator:	Aviv M Weinstein, Ph.D	Tel-Aviv Sourasky Medical Center
Study Director:	Hedva Lerman, M.D	Tel-Aviv Sourasky Medical Center

Information Provided By

Tel-Aviv Sourasky Medical Center

Verification Date

May 2008

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP